Key Events This Week
20 Apr: New 52-week high at Rs.2,091 and all-time high near Rs.1,999
21 Apr: Fresh 52-week and all-time highs at Rs.2,138.6 and Rs.2,134.95
22 Apr: New 52-week and all-time highs at Rs.2,141 amid sector outperformance
24 Apr: Week closes at Rs.2,112.90 after hitting Rs.2,149.9 high
Monday, 20 April 2026: Breakout to New Highs
Fredun Pharmaceuticals began the week with a striking 12.43% gain, closing at Rs.2,067.70, propelled by a new 52-week high of Rs.2,091. This surge marked a continuation of a strong rally, with the stock outperforming the Sensex which marginally declined 0.02%. The day’s volume of 33,033 shares reflected heightened investor interest. The stock’s rise was supported by robust financials, including a 56.70% year-on-year increase in quarterly net sales to Rs.160.93 crores and record operating profits. Promoter stake increased by 1.11% to 44.17%, signalling confidence in the company’s prospects. Technical indicators such as MACD and Bollinger Bands confirmed the bullish momentum.
Tuesday, 21 April 2026: Continued Momentum and New Records
On 21 April, the stock extended gains by 1.15% intraday, closing at Rs.2,043.90, despite a slight dip from Monday’s close. However, intraday highs reached Rs.2,138.6, setting a fresh 52-week and all-time high. The stock outperformed the Sensex’s 0.77% gain, supported by strong delivery volumes and sustained buying interest. The company’s financial strength remained a key driver, with operating profit growth of 58.31% and a healthy ROCE of 20.2%. The Sensex closed at 36,091.30, reflecting a positive market backdrop, but Fredun’s gains were more pronounced, underscoring its sector leadership.
Just announced: This Small Cap from Tyres & Allied with precise target price is our pick for the week. Get the pre-market insights that informed this selection!
- - Just announced pick
- - Pre-market insights shared
- - Tyres & Allied weekly focus
Wednesday, 22 April 2026: Resilience Amid Market Weakness
Fredun Pharmaceuticals closed at Rs.2,085.00, up 2.01%, hitting a new 52-week and all-time high of Rs.2,141. This gain came despite the Sensex falling 0.23% to 36,009.59, highlighting the stock’s relative strength. The company’s fundamentals continued to impress, with a 99.09% increase in operating profit year-on-year and a PEG ratio of 0.6 indicating attractive valuation relative to growth. Promoter confidence remained strong, and technical indicators such as weekly and monthly MACD and Bollinger Bands signalled sustained bullish momentum. The stock’s ability to outperform in a cautious market environment underscores its robust positioning within the Pharmaceuticals & Biotechnology sector.
Thursday, 23 April 2026: Steady Gains and Technical Confirmation
The stock advanced 1.24% to close at Rs.2,110.85, maintaining its upward trajectory and setting new highs. The Sensex declined 0.78%, reinforcing Fredun Pharmaceuticals’ outperformance. Delivery volumes remained steady, and the stock traded above all key moving averages, confirming the bullish trend. The company’s consistent quarterly results, including record PBDIT of Rs.26.34 crores and profit before tax of Rs.14.00 crores, continued to underpin investor confidence. The promoter stake increase and absence of pledged shares further strengthened the stock’s appeal.
Get the full story on Fredun Pharmaceuticals Ltd! Our detailed research dives into fundamentals, sector comparison, technical analysis, and valuations for this micro-cap. Make informed decisions!
- - Full research story
- - Sector comparison done
- - Informed decision support
Friday, 24 April 2026: Week Closes Near Record Highs
Fredun Pharmaceuticals closed the week at Rs.2,112.90, up 0.10% on the day, after reaching a new 52-week high of Rs.2,149.9. This marked a cumulative weekly gain of 14.88%, vastly outperforming the Sensex’s 1.31% decline. The stock’s resilience amid a weak broader market, which saw the Sensex fall 1.06% to 35,349.66, highlights its strong fundamentals and technical strength. The company’s return on capital employed of 20.2%, consistent profit growth, and rising promoter stake underpin this performance. Technical indicators remain bullish, with no signs of overextension, suggesting continued investor confidence.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-04-20 | Rs.2,067.70 | +12.43% | 35,814.68 | -0.02% |
| 2026-04-21 | Rs.2,043.90 | -1.15% | 36,091.30 | +0.77% |
| 2026-04-22 | Rs.2,085.00 | +2.01% | 36,009.59 | -0.23% |
| 2026-04-23 | Rs.2,110.85 | +1.24% | 35,729.71 | -0.78% |
| 2026-04-24 | Rs.2,112.90 | +0.10% | 35,349.66 | -1.06% |
Key Takeaways
Strong Financial Growth: Fredun Pharmaceuticals demonstrated exceptional growth with a 56.70% increase in quarterly net sales and a 99.09% rise in operating profit year-on-year, underpinning the stock’s rally.
Promoter Confidence: The promoter stake increased by 1.11% to 44.17%, signalling strong insider belief in the company’s prospects and governance.
Technical Strength: The stock consistently traded above all key moving averages, supported by bullish MACD, Bollinger Bands, and Dow Theory indicators on weekly and monthly charts.
Market Outperformance: The stock outperformed the Sensex by over 16 percentage points during the week, highlighting its resilience amid a broadly weak market.
Valuation Metrics: With a PEG ratio around 0.6 and a reasonable price-to-earnings ratio near 35x, the stock appears attractively valued relative to its earnings growth.
Conclusion
Fredun Pharmaceuticals Ltd’s impressive 14.88% weekly gain amid a declining Sensex reflects a compelling combination of strong financial results, rising promoter confidence, and robust technical momentum. The stock’s ability to set multiple new 52-week and all-time highs during the week underscores its leadership within the Pharmaceuticals & Biotechnology sector. Despite a challenging broader market environment, Fredun Pharmaceuticals has demonstrated resilience and sustained growth, supported by consistent quarterly earnings improvements and positive market sentiment. Investors monitoring this micro-cap should note its strong fundamentals and technical positioning as key factors behind its recent outperformance.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
